{"id":724,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"cjc-1295-dac-randomized-human-pharmacology","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/fr\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","title":{"rendered":"CJC-1295 avec DAC\u00a0: pharmacologie humaine randomis\u00e9e et limite de liaison \u00e0 l'albumine"},"content":{"rendered":"<h2>La question de l\u2019identit\u00e9 passe avant le r\u00e9sultat<\/h2>\n<p>Le compos\u00e9 cit\u00e9 a \u00e9t\u00e9 con\u00e7u comme un analogue du GHRH \u00e0 action prolong\u00e9e qui se lie \u00e0 l\u2019albumine endog\u00e8ne. Cette caract\u00e9ristique de conception est au c\u0153ur de la question pharmacocin\u00e9tique. Les pages de recherche regroupent fr\u00e9quemment \u00ab avec DAC \u00bb et \u00ab sans DAC \u00bb en un seul nom, mais cela modifie l'identit\u00e9 mol\u00e9culaire et invalide un transfert direct de la demi-vie rapport\u00e9e.<\/p>\n<h2>Ce que les essais ont mesur\u00e9<\/h2>\n<p>Les deux essais \u00e9taient randomis\u00e9s, contr\u00f4l\u00e9s par placebo, en double aveugle et \u00e0 dose croissante. Leurs principaux crit\u00e8res de jugement \u00e9taient l\u2019exposition circulante aux GH et IGF-I ainsi que les param\u00e8tres pharmacocin\u00e9tiques. Ce sont des param\u00e8tres pharmacologiques. Il ne s\u2019agit pas de mesures directes de l\u2019am\u00e9lioration de la sant\u00e9, de la composition corporelle ou des performances.<\/p>\n<h2>Le cours du temps rapport\u00e9<\/h2>\n<p>Les auteurs ont rapport\u00e9 des augmentations soutenues et dose-d\u00e9pendantes de GH et de IGF-I et une demi-vie estim\u00e9e mesur\u00e9e en jours. Une \u00e9tude compl\u00e9mentaire a rapport\u00e9 que la s\u00e9cr\u00e9tion pulsatile de GH restait observable sous un stimulus prolong\u00e9. Ces enregistrements prennent en charge une discussion m\u00e9caniste et temporelle pour le formulaire DAC uniquement.<\/p>\n<div class=\"pfm-case-callout\"><strong>V\u00e9rification du nom\u00a0:<\/strong> une page qui utilise l'essai classique CJC-1295 pour d\u00e9crire \u00ab CJC-1295 sans DAC \u00bb m\u00e9lange deux mat\u00e9riaux distincts. L'identit\u00e9 du produit doit correspondre \u00e0 l'intervention cit\u00e9e avant qu'un num\u00e9ro ne soit r\u00e9utilis\u00e9.<\/div>\n<h2>Ce que l\u2019\u00e9tude n\u2019\u00e9tablit pas<\/h2>\n<p>De courtes donn\u00e9es sur les hormones et l'exposition en phase pr\u00e9coce n'\u00e9tablissent pas l'efficacit\u00e9 th\u00e9rapeutique, la s\u00e9curit\u00e9 \u00e0 long terme ou la qualit\u00e9 d'un lot commercial. Un lot actuel n\u00e9cessite sa propre documentation d'identit\u00e9, d'analyse et de lib\u00e9ration\u00a0; la litt\u00e9rature ne peut pas remplacer ces contr\u00f4les.<\/p>","protected":false},"excerpt":{"rendered":"<p>Une lecture attentive de deux \u00e9tudes randomis\u00e9es \u00e0 dose croissante chez des adultes en bonne sant\u00e9, ax\u00e9es sur les \u00e9volutions temporelles de GH et de IGF-I, la demi-vie estim\u00e9e et les raisons pour lesquelles les r\u00e9sultats ne s'appliquent pas \u00e0 CJC-1295 sans DAC.<\/p>","protected":false},"author":0,"featured_media":852,"template":"","class_list":["post-724","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CJC-1295 DAC Human Trial: GH, IGF-I and Half-Life<\/title>\n<meta name=\"description\" content=\"A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do not apply to CJC-1295 without DAC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CJC-1295 With DAC: Randomized Human Pharmacology and the Albumin-Binding Boundary\" \/>\n<meta property=\"og:description\" content=\"A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do not apply to CJC-1295 without DAC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/\",\"name\":\"CJC-1295 DAC Human Trial: GH, IGF-I and Half-Life\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cjc-1295-dac-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do not apply to CJC-1295 without DAC.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cjc-1295-dac-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cjc-1295-dac-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial laboratory illustration; not an image of a supplied lot or a reported analytical result.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CJC-1295 With DAC: Randomized Human Pharmacology and the Albumin-Binding Boundary\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Essai humain CJC-1295 DAC\u00a0: GH, IGF-I et Half-Life","description":"Une lecture attentive de deux \u00e9tudes randomis\u00e9es \u00e0 dose croissante chez des adultes en bonne sant\u00e9, ax\u00e9es sur les \u00e9volutions temporelles de GH et de IGF-I, la demi-vie estim\u00e9e et les raisons pour lesquelles les r\u00e9sultats ne s'appliquent pas \u00e0 CJC-1295 sans DAC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","og_locale":"fr_FR","og_type":"article","og_title":"CJC-1295 With DAC: Randomized Human Pharmacology and the Albumin-Binding Boundary","og_description":"A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do not apply to CJC-1295 without DAC.","og_url":"https:\/\/nhdbio.com\/fr\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","url":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","name":"Essai humain CJC-1295 DAC\u00a0: GH, IGF-I et Half-Life","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"Une lecture attentive de deux \u00e9tudes randomis\u00e9es \u00e0 dose croissante chez des adultes en bonne sant\u00e9, ax\u00e9es sur les \u00e9volutions temporelles de GH et de IGF-I, la demi-vie estim\u00e9e et les raisons pour lesquelles les r\u00e9sultats ne s'appliquent pas \u00e0 CJC-1295 sans DAC.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial laboratory illustration; not an image of a supplied lot or a reported analytical result."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"CJC-1295 With DAC: Randomized Human Pharmacology and the Albumin-Binding Boundary"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study\/724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study\/724\/revisions"}],"predecessor-version":[{"id":729,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study\/724\/revisions\/729"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/852"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}